7月14日电，葛兰素史克表示，已向美国FDA提交申请，将其呼吸道合胞病毒（RSV）疫苗Arexvy的使用范围扩大到18岁至49岁、患病风险较高的成年人。

Core Viewpoint - GlaxoSmithKline has submitted an application to the U.S. FDA to expand the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18 to 49 who are at higher risk of illness [1] Group 1 - The application aims to broaden the vaccine's target demographic, potentially increasing its market reach and sales [1] - The RSV vaccine Arexvy is currently approved for specific populations, and this expansion could address a larger segment of the adult population [1]